Wolwo Bio-Pharmaceutical's S01D Tablet Clinical Trial Application Accepted by NMPA for Drug-Resistant TB

Wolwo Bio-Pharmaceutical issued an announcement stating that it has received the Acceptance Notice from the National Medical Products Administration (NMPA), and that its clinical trial application for S01D tablets has been formally accepted. The drug exhibits activity against Mycobacterium tuberculosis and is intended for the treatment of adult patients with drug-resistant pulmonary tuberculosis. As of the announcement date, no identical chemical drug has been approved for marketing in China or overseas.